Severe Liver Injury Associated With High-Dose Atorvastatin Therapy

Amit Saha, Abhimanyu Garg

Research output: Contribution to journalArticlepeer-review

5 Scopus citations


Statins are recommended for first-line management of elevated cholesterol in the primary and secondary prevention of atherosclerotic cardiovascular disease. Statins may occasionally be associated with mild transaminase elevations but can also result in life-threatening liver injury. Atorvastatin is the most common cause of clinically significant liver injury in this drug class. We report a case of severe, asymptomatic liver injury in a hepatocellular pattern in a 71-year-old man occurring within 3 months of switching from simvastatin to high-intensity atorvastatin therapy. Hepatitis improved rapidly with cessation of atorvastatin and did not recur after resuming simvastatin.

Original languageEnglish (US)
JournalJournal of Investigative Medicine High Impact Case Reports
StatePublished - 2021


  • atorvastatin
  • drug-induced liver injury
  • hepatocellular injury
  • simvastatin
  • statins
  • transaminitis

ASJC Scopus subject areas

  • Epidemiology
  • Safety, Risk, Reliability and Quality
  • Safety Research


Dive into the research topics of 'Severe Liver Injury Associated With High-Dose Atorvastatin Therapy'. Together they form a unique fingerprint.

Cite this